The BRC team visited the Stevenage Bioscience Catalyst (SBC) this week to see for themselves how UCL projects that have taken up laboratory space there were getting on.
BRC-supported research has received a £10 million award to develop better tools, imaging techniques and therapies in future operations on unborn babies. Image courtesy of Wellcome Images
Applications are invited for funding of up to £1 million, four awards of up to £250,000, for Neurosciences research under the BRC ‘Big Questions’ scheme.
A third of epilepsy sufferers do not respond to present medications so it is vital new treatments for this population are found, according to BRC Professor Matthew Walker who is Head of Clinical and Experimental Epilepsy at the UCL Institute of Neurology.
UCL researchers will feature on BBC’s Horizon tonight, taking part in a ground-breaking piece of engagement where the public will choose where £10 million will go.
UCL Business, Imperial Innovations and the Cell Therapy Catapult have formed a partnership to develop a novel cell therapy approach to the treatment of acute myeloid leukaemia.
Congratulations to BRC researcher Dr Teresa Marafioti who has been awarded a prize for the most outstanding original article to be published in the journal Histopathology in 2013.
The Centre for Cardiovascular Genetics , part of the UCL Institute of Cardiovascular Science, is looking to recruit a Senior Cardiovascular Biocurator.
Combination chemotherapy results in higher response rates but does not confer an overall survival advantage compared with single-dose chemotherapy in patients with advanced or metastatic soft-tissue sarcoma, according to findings published in The Lancet Oncology.
Researchers have has proposed a review of World Health Organization (WHO) recommendations on optimal timing of antiretroviral therapy in HIV-positive patients with high CD4+ T cell counts undergoing treatment for tuberculosis.
Doctors are now using genetic information in an effort to identify and prevent heart problems in patients who seem healthy but may be at risk because of a family history of heart diseases, says Professor Steve Humphries.
A new type of implantable cardioverter defibrillator (ICD) performs just as well as the conventional kind, according to results from an international study. Image courtesy of Wellcome Photo Library, Wellcome Images
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
